Oxaliplatine, fluoro-uracile et leucovorine: traitements adjuvants des cancers du côlon

Aparicio, Thomas

doi:10.1007/s11725-011-0275-8

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multidrug chemotherapy regimens are widely used for treatment in both the adjuvant and metastatic setting. Fluoropyrimidine-based agents are the backbone of therapy and commonly used systemic treatment combinations include folinic acid/fluorouracil/oxaliplatin (FOLFOX), folinic acid/fluorouracil/irinotecan (FOLFIRI) or capecitabine/oxaliplatin (CAPOX) with or without monoclonal antibodies [ 2 , 3 , 4 , 5 ]. Although the routine uses of combination therapy is responsible for improved patient outcomes, it is also carries a significant risk of treatment related toxicity that can necessitate adjustment to the original chemotherapy plan to allow for recovery [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Virtual Cancer Care on Chemotherapy Delivery and Clinical Outcomes in Colorectal Cancer Patients Receiving Systemic Therapy: A Pre- and Intra-Pandemic Analysis

et al. 2022

View full text Add to dashboard Cite

(1) Background: The coronavirus 2019 pandemic has resulted in an abrupt transition to virtual oncology care worldwide. This study’s objective is to evaluate chemotherapy delivery and clinical outcomes in patients on systemic treatment for colorectal cancer before and during the pandemic. (2) Methods: Clinical data was collected on patients with colorectal cancer receiving intravenous chemotherapy at The Ottawa Hospital from June 2019 to March 2021. Patients were stratified by whether they were started on chemotherapy pre-pandemic (June 2019–January 2020) or intra-pandemic (February 2020–March 2021). Multiple regression analysis was used to compare outcomes between pandemic periods; (3) Results: There were 220 patients included in this study. The proportion of virtual consultations (1.2% to 64.4%) and follow-up visits (5.2% to 83.3%) increased during the pandemic. There was no difference in the incidence of treatment delays (OR = 1.01, p = 0.78), chemotherapy dose reductions (OR = 0.99, p = 0.69), emergency department visits (OR = 1.23, p = 0.37) or hospitalizations (OR = 0.73, p = 0.43) between pandemic periods. A subgroup analysis revealed no difference in outcomes independent of the presence of metastases; (4) Conclusion: These findings serve as an important quality-care indicator and demonstrate that virtual oncology care appears safe in a cohort of high-risk colorectal cancer patients.

show abstract